Crohn's Disease Market Insights Report Highlights Emerging Trends and Potential Therapies

Strategic Insights -

The Crohn's Disease Market Insights report by DelveInsight provides a comprehensive understanding of the current treatment landscape, emerging therapies, and market share of individual therapies. The report highlights the growing demand for effective Crohn's disease treatments, with an estimated 2.1 million diagnosed prevalent cases in the 7MM (the United States, the EU4, and the United Kingdom) in 2024.

Key Takeaways:

  • The Crohn's disease market size was found to be USD 10.8 billion in the 7MM, with approximately 8-10% being the pediatric market in 2024.
  • Adalimumab (HUMIRA and its generics) accounted for the highest market share of ~USD 4 billion in 2024 for the treatment of Crohn's disease in the 7MM.
  • Almost 200,000 cases of Crohn's disease are pediatric, and it was estimated that almost 60% of the cases were within the moderate-to-severe category in 2024.
  • RedHill Biopharma, Merck, Teva Pharmaceutical, Pfizer, Agomab Therapeutics, Sanofi, Medibiofarma, Eli Lilly, NImmune, Avobis Bio, Abivax, Roche, Telavant, Mesoblast, Takeda, AstraZeneca, and others are developing emerging therapies for Crohn's disease.
  • Promising Crohn's disease therapies in the pipeline include RHB-104, Tulisokibart (MK-7240, PRA023), Duvakitug (TEV-574), LITFULO (Ritlecitinib/PF-06651600), AGMB-129, Balinatunfib (SAR441566), MBF-118, MORF-057, Omilancor (BT-11), AVB-114, Obefazimod (ABX464), Afimkibart (RVT-3101 or RG6631), RYONCIL (Remestemcel-L), Zasocitinib (TAK-279), AZD7798, and others.

Statistics:

  • Estimated 2.1 million diagnosed prevalent cases of Crohn's disease in the 7MM in 2024.
  • 8-10% of the 2024 Crohn's disease market is in the pediatric segment.
  • Adalimumab (HUMIRA and its generics) held a market share of ~USD 4 billion in 2024.
  • Almost 60% of Crohn's disease cases were within the moderate-to-severe category in 2024.

Sources:

  • DelveInsight's Crohn's Disease Market Insights report
  • RedHill Biopharma
  • Merck
  • Teva Pharmaceutical
  • Pfizer
  • Agomab Therapeutics
  • Sanofi
  • Medibiofarma
  • Eli Lilly
  • NImmune
  • Avobis Bio
  • Abivax
  • Roche
  • Telavant
  • Mesoblast
  • Takeda
  • AstraZeneca